Mayo Clinic, Transplant Genomics to develop immunosuppression strategies for transplant patients
Mayo Clinic and molecular diagnostics company Transplant Genomics are teaming up to develop and commercialize diagnostic tests that will enable personalized immunosuppression for suitable organ transplant recipients.
The Mayo Clinic, based in Rochester, Minn., is investing in the assessment of Transplant Genomics’ TruGraf test designed for renal transplant monitoring, according to a statement from the organizations. Additionally, the two companies will development new tests and technologies for heart and liver transplants based on the TruGraf model.
Research will be completed at Mayo’s campuses in Arizona, Florida and Minnesota by Mayo physicians Mark Stegall, Raymond Heilman and Martin Mai.
"At Mayo, our research in this area is focused on improving long-term kidney graft survival, so that patients would lead healthier lives," said Stegall in a statement. “Genomic analysis of blood can reveal early signs of rejection in transplanted kidneys. The potential clinical utility is to be able to monitor for rejection more frequently than is possible with surveillance biopsies and to individualize immunosuppression in transplant recipients.”
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.